COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

Home・Stock List・CSL Ltd

CSL Ltd

Closed

Sector

303.69 0.59

Buy Sell

Overview

Share price change

24h

Current

Min

303.19

Max

304.27

Key metrics
By Trading Economics
Income	1.9B
Sales	8.1B
EPS	4.159
Profit margin	23.606

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+6.31 upside

Market Stats
By TradingEconomics
Market Cap	-686M 148B
Previous open	303.1
Previous close	303.69

News Sentiment

By Acuity

37%

63%

92 / 382 Industrials

CSL Ltd Chart

Related News

12 Aug 2024, 23:23 UTC

Earnings

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 Aug 2024, 22:49 UTC

Earnings

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

12 Feb 2024, 22:16 UTC

Earnings

CSL Says 1st Half Profit Rises, Boosts Dividend -- Update

12 Feb 2024, 22:00 UTC

Earnings

CSL Says 1st Half Profit Rises, Boosts Dividend

13 Aug 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 Aug 2024, 22:34 UTC

Earnings

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 Aug 2024, 22:18 UTC

Earnings

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 Aug 2024, 22:18 UTC

Earnings

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 Aug 2024, 22:17 UTC

Earnings

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 Aug 2024, 22:16 UTC

Earnings

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 Aug 2024, 22:15 UTC

Earnings

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 Aug 2024, 22:14 UTC

Earnings

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 Aug 2024, 22:13 UTC

Earnings

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 Aug 2024, 22:13 UTC

Earnings

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 Aug 2024, 22:11 UTC

Earnings

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 Aug 2024, 22:10 UTC

Earnings

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 Aug 2024, 22:09 UTC

Earnings

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 Aug 2024, 22:08 UTC

Earnings

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 Aug 2024, 22:07 UTC

Earnings

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

12 Aug 2024, 22:07 UTC

Earnings

CSL Final Dividend US$1.45/Share

13 Feb 2024, 01:50 UTC

Market Talk

Earnings

CSL Still Confident on Long-Term Value at Vifor Business -- Market Talk

13 Feb 2024, 00:39 UTC

Market Talk

Earnings

UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

12 Feb 2024, 22:01 UTC

Earnings

CSL Says 1H Profit Rises, Boosts Dividend -- Update

12 Feb 2024, 21:45 UTC

Peer Comparison

Price change

CSL Ltd Forecast

Price Target

By TipRanks

6.31% upside

12 Months Forecast

Average 323.182 AUD 6.31%

High 352 AUD

Low 278 AUD

Based on 12 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to CSL Ltd - Dist in the past 3 months.

Sentiment

By Acuity

92 / 382

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CSL Ltd

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.